N-(6-aminohexyl)-1-naphthalenesulfonamide hydrochloride

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: N-(6-aminohexyl)-1-naphthalenesulfonamide hydrochloride
• 英文别名: W5 hydrochloride；N-(6-aminohexyl)-1-napthalensulfonamide hydrochloride；N-(6-aminohexyl)-1-naphthalensulfonamide hydrochloride；N-(6-aminohexyl)naphthalene-1-sulfonamide;hydron;chloride
• 化学式: C₁₆H₂₂N₂O₂S*ClH
• mdl: MFCD00058043
• 分子量: 342.89
• InChiKey: HOCSVIGHWPLMFC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.85
• 重原子数：
  22
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  80.6
• 氢给体数：
  3
• 氢受体数：
  4

文献信息

• Aryl sulfonamides and sulfamide derivatives and uses thereof
  申请人：Synaptic Pharmaceutical Corporation

  公开号：US20030013714A1

  公开（公告）日：2003-01-16

  This invention is directed to novel aryl sulfonamide and sulfamide compounds which bind selectively to and inhibit the activity of the human Y5 receptor. This invention is also related to uses of these compounds for the treatment of feeding disorders such as obesity, anorexia nervosa, bulimia nervosa, and abnormal conditions such as sexual/reproductive disorders, depression, epileptic seizure, hypertension, cerebral hemorrhage, congestive heart failure or sleep disturbances and for the treatment of any disease in which antagonism of a Y5 receptor may be useful.

  本发明涉及新型芳基磺酰胺和磺酰胺化合物，其选择性地结合并抑制人类Y5受体的活性。本发明还涉及这些化合物在治疗进食障碍，如肥胖症、厌食症、贪食症和异常情况，如性/生殖障碍、抑郁症、癫痫发作、高血压、脑出血、充血性心力衰竭或睡眠障碍等方面的用途，以及在治疗任何可能有用的Y5受体拮抗作用的疾病方面的用途。
• Use of a modulator of protein phosphorylation in the treatment of amyloidosis associated with Alzheimer's disease
  申请人：THE ROCKEFELLER UNIVERSITY

  公开号：EP0457295A2

  公开（公告）日：1991-11-21

  Disclosed is the use of at lease one kinase modulator or phosphatase modulator being capable of increasing or decreasing the rate of proteolytic processing of proteins found in intracellular neurofibrillary tangles and extracellular amyloid plaques for the preparation of a pharmaceutical composition for the treatment of amyloidosis associated with Alzheimer's disease, wherein said pharmaceutical composition contains said modulator in an amount effectively regulating phosphorylation of said proteins.

  公开了至少一种激酶调节剂或磷酸酶调节剂的用途，它们能够提高或降低细胞内神经纤维缠结和细胞外淀粉样斑块中蛋白质的蛋白水解处理速度，用于制备治疗与阿尔茨海默病相关的淀粉样变性的药物组合物，其中所述药物组合物含有所述调节剂，其用量可有效调节所述蛋白质的磷酸化。
• SERCA inhibitor and Calmodulin antagonist combination
  申请人：Universität des Saarlandes

  公开号：EP2796137A1

  公开（公告）日：2014-10-29

  The present invention relates to novel combinations of active ingredients for use in the prevention and/or treatment of tumors. The tumors treated by the composition according to the invention overexpress SEC62 gene and overproduce Sec62 protein. The combination of active ingredients comprises at least a SERCA inhibitor and at least a Calmodulin antagonist.

  本发明涉及用于预防和/或治疗肿瘤的新型活性成分组合。根据本发明的组合物治疗的肿瘤过度表达 SEC62 基因并过度产生 Sec62 蛋白。活性成分组合至少包括一种 SERCA 抑制剂和至少一种钙调蛋白拮抗剂。
• CALCIUM CHANNEL BLOCKERS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES
  申请人：Children's Medical Center Corporation

  公开号：EP3461482A1

  公开（公告）日：2019-04-03

  The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).

  本发明一般涉及用于治疗核糖体紊乱和核糖体病（如菱形黑帆贫血症（DBA））的方法、组合物和试剂盒。在某些实施方案中，本发明涉及使用钙调蛋白抑制剂和钙通道阻滞剂治疗核糖体紊乱和核糖体病（如钻石黑范贫血症（DBA））的方法。
• Calmodulin inhibitors for the treatment of ribosomal disorders and ribosomapathies
  申请人：CHILDREN'S MEDICAL CENTER CORPORATION

  公开号：US10420778B2

  公开（公告）日：2019-09-24

  The present invention relates generally to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to methods for the use of calmodulin inhibitors and calcium channel blockers for treatment of ribosomal disorders and ribosomopathy, e.g. Diamond Blackfan anemia (DBA).

  本发明一般涉及用于治疗核糖体紊乱和核糖体病（如菱形黑帆贫血症（DBA））的方法、组合物和试剂盒。在某些实施方案中，本发明涉及使用钙调蛋白抑制剂和钙通道阻滞剂治疗核糖体紊乱和核糖体病（如钻石黑范贫血症（DBA））的方法。